GHRS Latest Headlines

Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION)

at www.tipranks.com (Fri, 6-Mar 8:50 PM)

Stifel Nicolaus Sticks to Their Buy Rating for GH Research (GHRS)

at www.tipranks.com (Fri, 6-Mar 6:58 AM)

Canaccord Genuity Reaffirms Their Buy Rating on GH Research (GHRS)

at www.tipranks.com (Fri, 6-Mar 6:58 AM)

GH Research’s Phase 2b Success in Depression Marks Major Milestone—$280.7M Cash Runway Backs Phase 3 Ambitions

Market Chameleon (Thu, 5-Mar 9:10 AM)

GH Research GAAP EPS of -$0.79

at seekingalpha.com (Thu, 5-Mar 5:00 PM)

GH Research: Phase 3 Readiness, Expanding Indications, and Valuation Upside Reinforce Buy Rating

at www.tipranks.com (Thu, 5-Mar 4:45 PM)

GH Research Posts 2025 Results as TRD Drug GH001 Clears Key Phase 2b Milestone

at www.tipranks.com (Thu, 5-Mar 7:29 AM)

GH Research Awaits Key FDA Decision on GH001 as Phase 3 Depression Trial Advances

Market Chameleon (Mon, 5-Jan 10:31 AM)

FDA Greenlights GH001 for U.S. Trials—Phase 3 Launch Set for 2026 as Rapid-Acting Antidepressant Shows Promise

Market Chameleon (Mon, 5-Jan 7:05 AM)